Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about QURE, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2027-05-01 | ifezuntirgene inilparvovec | Huntington's disease | BLA | 52% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Alipogene Tiparvovec | LPL Deficiency | Phase 2 · NCT02904772 | Withdrawn |
| AMT-162 | Amyotrophic Lateral Sclerosis | Phase 1/2 · NCT06100276 | Active not recruiting |
| AMT-191 | Fabry Disease | Phase 1/2 · NCT06270316 | Recruiting |
| Cyclosporins | LPL Deficiency | Phase 2 · NCT02904772 | Withdrawn |
| Prednisolone | LPL Deficiency | Phase 2 · NCT02904772 | Withdrawn |
| rAAV2/5-hNAGLU | Sanfilippo Syndrome B | Phase 1/2 · NCT03300453 | Completed |
Also used in these trials (approved or third-party drugs, not QURE's own candidates): Mycophenolate Mofetil.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
QURE holds $768.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $38.2M/quarter from operations, an estimated runway of 60.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
We believe these resources will be sufficient to fund our projected operating expenses into 2030, including costs associated with the commercial launches and confirmatory study of ifezuntirgene inilparvovec, ongoing clinical trials of ifezuntirgene inilparvovec, AMT-191 and AMT-260, and potential investments to…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when QURE files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | Institution (13G, 5%+) | 6,150,000 | 8.77% | 2025-12-31 |
| JPMORGAN CHASE & CO. | Institution (13G, 5%+) | 5,951,794 | 8.49% | 2026-09-30 |
| abrdn Inc. | Institution (13G, 5%+) | 5,306,386 | 7.57% | 2026-04-01 |
| RTW Investments, LP | Institution (13G, 5%+) | 3,941,572 | 5.62% | 2026-06-30 |
| Matthew C Kapusta CEO, Managing Director, Director · +159,662 options |
Insider | 519,227 | 0.74% | 2026-07-02 |
| Christian Klemt Chief Financial Officer · +63,900 options |
Insider | 226,581 | 0.32% | 2026-03-04 |
| Walid Abi-Saab Chief Medical Officer · +117,700 options |
Insider | 166,985 | 0.24% | 2026-10-30 |
| Jeannette Potts Chief Legal Officer · +57,200 options |
Insider | 133,246 | 0.19% | 2026-06-15 |
| Kylie O'Keefe Chief Customer & Strat Officer · +31,900 options |
Insider | 108,864 | 0.16% | 2026-06-11 |
| Madhavan Balachandran Director · +13,980 options |
Insider | 43,254 | 0.06% | 2026-06-17 |
| Jeremy P. Springhorn Director · +13,980 options |
Insider | 43,251 | 0.06% | 2026-06-10 |
| Leonard E Post Director · +13,980 options |
Insider | 35,494 | 0.05% | 2026-06-10 |
Share count 70,138,860 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QURE and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →